PRAVASTATIN TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

PRAVASTATIN SODIUM

Disponible desde:

SIVEM PHARMACEUTICALS ULC

Código ATC:

C10AA03

Designación común internacional (DCI):

PRAVASTATIN

Dosis:

40MG

formulario farmacéutico:

TABLET

Composición:

PRAVASTATIN SODIUM 40MG

Vía de administración:

ORAL

Unidades en paquete:

15G/50G

tipo de receta:

Prescription

Área terapéutica:

HMG-COA REDUCTASE INHIBITORS

Resumen del producto:

Active ingredient group (AIG) number: 0122563003; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2022-09-21

Ficha técnica

_PRAVASTATIN Product Monograph_
Page 1 of 40
PRODUCT MONOGRAPH
Pr
PRAVASTATIN
pravastatin sodium tablets USP
10 mg, 20 mg and 40 mg
Lipid Metabolism Regulator
SIVEM PHARMACEUTICALS ULC
4705 Dobrin Street
Saint-Laurent, Quebec, Canada
H4R 2P7
www.sivem.ca
CONTROL NUMBER: 280722
DATE OF
PREPARATION:
JUL
23, 2012
DATE
OF
REVISION
NOV 27, 2023
_PRAVASTATIN Product Monograph_
Page 2 of 40
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
5
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................16
DOSAGE AND ADMINISTRATION
..............................................................................18
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................22
PART II: SCIENTIFIC INFORMATION
..............................................................................
23
PHARMACEUTICAL INFORMATION
.........................................................................23
CLINICAL TRIALS
........................................................................................................